The present invention relates to systems for filling containers with dry powder such as drugs, chemicals and toners and may be particularly suitable for filling multi-dose disks or other containers for dry powder inhalers.
Known dry powder dose filling devices use injectors, pistons or sleeves, such as described in U.S. Pat. Nos. 3,847,191, 4,116,247, 4,850,259, and 6,886,612. These systems typically use feed systems such as auger or vibratory table based replenishment systems. Despite the above, there remains a need for alternate feed systems for filling systems.
Embodiments of the invention provide dry powder feeders that can replenish dry powder filling heads.
Embodiments of the invention can be used with dry powder filling systems that meter doses of dry powder into dose containers suitable for use in inhalers.
Embodiments of the invention may replace conventional augers or vibrating tray feeds that feed dosing heads.
Embodiments of the invention are directed to tubular feed systems with an in-line actuator that applies a flow vibration signal axially. The flow vibration signal can be a harmonic or non-harmonic signal, such as a sinusoidal, saw tooth, square wave or other signal and may be frequency or amplitude modulated.
Some embodiments are directed to dry powder feeder systems. The systems include: (a) a hopper configured to hold dry powder therein; (b) an elongate tube in communication with the hopper, the elongate tube extending axially downward at a defined angle, the tube having opposing upper and lower end portions and a flange having upper and lower primary surfaces extending outwardly from the tube between the upper and lower end portions, the upper end portion being in fluid communication with the hopper so that, during operation, dry powder from the hopper can flow through the tube; and (c) an actuator having an open center space defining a through channel and opposing upper and lower ends, the tube extending through the actuator channel with the actuator lower end residing proximate the upper primary surface of the tube flange. The actuator is configured to apply a vibration signal to the tube in an axial direction.
The system may include: (d) a resilient member residing proximate the flange lower primary surface; and (e) a rigid mounting member with a channel that allows the tube to extend therethrough. The actuator can be mounted to the mounting member in a pre-load configuration so that, during operation, the tube moves axially between about 2-20 microns during application of the vibration signal.
The system may include: (d) a resilient member residing proximate the flange lower primary surface; and (e) a rigid mounting member having a cavity that encloses a portion of the tube including the tube flange and the resilient member. The actuator can be mounted to the mounting member in a pre-load configuration so that, during operation, the tube moves axially between about 2-20 microns during application of the vibration signal.
The system may also include: (d) a resilient member residing proximate the flange lower primary surface; (e) a retention member having a center channel residing below the resilient member, the tube extending through the retention member channel, the retention member having an upper primary surface that contacts the resilient member; and (f) a mounting member residing above the retention member, the mounting member having an axially extending channel through which the tube extends. The actuator upper end portion can be attached to the mounting member and the retention member can also be attached to the mounting member. The retention member is attached to the mounting member in a pre-load configuration so that during operation, the tube moves axially between about 0.5-20 microns during application of the vibration signal.
In some embodiments, the feed systems can include a single hopper that feeds multiple elongate tubes for replenishing one or more dosing heads or dry powder beds.
Other embodiments are directed to methods of replenishing a dry powder bed associated with a dry powder filling system. The methods include: (a) providing a tube oriented at an angle of between about 15 degrees to about 75 degrees from horizontal; (b) axially applying vibration to the tube to regulate powder flow through the tube; and (c) capturing the dry powder, at least temporarily, in a hopper residing at a downstream end portion of the tube.
The tube can extend through an actuator with an open axially extending center channel. The applying step may be carried out based on vibration transmitted by the actuator causing the tube to reciprocate axially and compress a resilient member. The method may also include controlling a duration (e.g., “on” time) of the applying step to meter a defined amount of dry powder to a dry powder bed so that the flow is “on” in response to the axially applied vibration step and the flow is “off” when the axially applying step stops.
The method can include tuning the responsiveness of the tube to the vibration by selecting a wall thickness to obtain free motion when the vibration is applied and no motion when the vibration is removed, wherein the powder flows through the tube at a rate of between about 100-500 mg/second (or optionally even faster flow rates) during the axially applying step.
It is noted that aspects of the invention described with respect to one embodiment or figure, may be incorporated in a different embodiment although not specifically described relative thereto. That is, all embodiments and/or features of any embodiment can be combined in any way and/or combination. Applicant reserves the right to change any originally filed claim or file any new claim accordingly, including the right to be able to amend any originally filed claim to depend from and/or incorporate any feature of any other claim although not originally claimed in that manner. These and other objects and/or aspects of the present invention are explained in detail in the specification set forth below.
The present invention will now be described more fully hereinafter with reference to the accompanying figures, in which embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Like numbers refer to like elements throughout. In the figures, certain layers, components or features may be exaggerated for clarity, and broken lines illustrate optional features or operations unless specified otherwise. In addition, the sequence of operations (or steps) is not limited to the order presented in the figures and/or claims unless specifically indicated otherwise. In the drawings, the thickness of lines, layers, features, components and/or regions may be exaggerated for clarity and broken lines illustrate optional features or operations, unless specified otherwise. Features described with respect to one figure or embodiment can be associated with another embodiment of figure although not specifically described or shown as such.
It will be understood that when a feature, such as a layer, region or substrate, is referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when an element is referred to as being “directly on” another feature or element, there are no intervening elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other element or intervening elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another element, there are no intervening elements present. Although described or shown with respect to one embodiment, the features so described or shown can apply to other embodiments.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation or relative descriptor only unless specifically indicated otherwise.
It will be understood that although the terms “first” and “second” are used herein to describe various components, regions, layers and/or sections, these regions, layers and/or sections should not be limited by these terms. These terms are only used to distinguish one component, region, layer or section from another component, region, layer or section. Thus, a first component, region, layer or section discussed below could be termed a second component, region, layer or section, and vice versa, without departing from the teachings of the present invention. Like numbers refer to like elements throughout.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. Well-known functions or constructions may not be described in detail for brevity and/or clarity.
In the description of the present invention that follows, certain terms are employed to refer to the positional relationship of certain structures relative to other structures. As used herein, the term “front” or “forward” and derivatives thereof refer to the general or primary direction that the dry powder travels to be dispensed to a patient from a dry powder inhaler; this term is intended to be synonymous with the term “downstream,” which is often used in manufacturing or material flow environments to indicate that certain material traveling or being acted upon is farther along in that process than other material. Conversely, the terms “rearward” and “upstream” and derivatives thereof refer to the direction opposite, respectively, the forward or downstream direction.
The term “deagglomeration” and its derivatives refer to flowing or processing dry powder to inhibit the dry powder from remaining or becoming agglomerated or cohesive.
The term “free-flow” refers to the ability of a channel to allow dry powder to flow therethrough when in an operative position and in the absence of any vibratory flow signal.
The filling systems can be particularly suitable for filling a partial or bolus dose or doses of one or more types of particulate dry powder substances that are formulated for in vivo inhalant dispersion (using an inhaler) to subjects, including, but not limited to, animal and, typically, human subjects. The inhalers can be used for nasal and/or oral (mouth) respiratory inhalation delivery, but are typically oral inhalers.
The term “primary surface” refers to a surface that has a greater area than another surface and the primary surface can be substantially planar or may be otherwise configured. For example, a primary surface can include protrusions or recessions, such as where some blister configurations are used. Thus, a component such as a disk and/or plate can have upper and lower primary surfaces and a minor surface (e.g., a wall with a thickness) that extends between and connects the two.
The dry powder substance may include one or more active pharmaceutical constituents as well as biocompatible additives that form the desired formulation or blend. As used herein, the term “dry powder” is used interchangeably with “dry powder formulation” and means that the dry powder can comprise one or a plurality of constituents, agents or ingredients with one or a plurality of (average) particulate size ranges. The term “low-density” dry powder means dry powders having a density of about 0.8 g/cm3 or less. In particular embodiments, the low-density powder may have a density of about 0.5 g/cm3 or less. The dry powder may be a dry powder with cohesive or agglomeration tendencies.
The term “filling” means providing a bolus or sub-bolus metered or defined amount of dry powder. Thus, the respective dose container is not required to be volumetrically full.
The term “direct” with respect to filling means that no additional components are required to carry out the operation, e.g., the dry powder is directly deposited from the dosing head channel into a blister or dose container.
As will be appreciated by one of skill in the art, embodiments or aspects of the invention may be embodied as a method, system, data processing system, or computer program product. Accordingly, the present invention may take the form of an entirely software embodiment or an embodiment combining software and hardware aspects, all generally referred to herein as a “circuit” or “module.”
In any event, individual dispensable quantities of dry powder formulations can comprise a single ingredient or a plurality of ingredients, whether active or inactive. The inactive ingredients can include additives added to enhance flowability or to facilitate aerosolization delivery to the desired target. The dry powder drug formulations can include active particulate sizes that vary. The systems may be particularly suitable for filling dry powder formulations having particulates which are in the range of between about 0.5-50 μm, typically in the range of between about 0.5 μm-20.0 μm, and more typically in the range of between about 0.5 μm-8.0 μm. The dry powder formulation can also include flow-enhancing ingredients, which typically have particulate sizes that may be larger than the active ingredient particulate sizes. In certain embodiments, the flow-enhancing ingredients can include excipients having particulate sizes on the order of about 50-100 μm. Examples of excipients include lactose and trehalose. Other types of excipients can also be employed, such as, but not limited to, sugars which are approved by the United States Food and Drug Administration (“FDA”) as cryoprotectants (e.g., mannitol) or as solubility enhancers (e.g., cyclodextrine) or other generally recognized as safe (“GRAS”) excipients.
“Active agent” or “active ingredient” as described herein includes an ingredient, agent, drug, compound, or composition of matter or mixture, which provides some pharmacologic, often beneficial, effect. This includes foods, food supplements, nutrients, drugs, vaccines, vitamins, and other beneficial agents. As used herein, the terms further include any physiologically or pharmacologically active substance that produces a localized and/or systemic effect in a patient.
The active ingredient or agent that can be delivered includes antibiotics, antiviral agents, anepileptics, analgesics, anti-inflammatory agents and bronchodilators, and may be inorganic and/or organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synoptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system, and the central nervous system. Suitable agents may be selected from, for example and without limitation, polysaccharides, steroids, hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, anti-inflammatories, muscle contractants, antimicrobials, antimalarials, hormonal agents including contraceptives, sympathomimetics, polypeptides and/or proteins (capable of eliciting physiological effects), diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics, hypoglycemics, nutritional agents and supplements, growth supplements, fats, antienteritis agents, electrolytes, vaccines and diagnostic agents.
The active agents may be naturally occurring molecules or they may be recombinantly produced, or they may be analogs of the naturally occurring or recombinantly produced active agents with one or more amino acids added or deleted. Further, the active agent may comprise live attenuated or killed viruses suitable for use as vaccines. Where the active agent is insulin, the term “insulin” includes natural extracted human insulin, recombinantly produced human insulin, insulin extracted from bovine and/or porcine and/or other sources, recombinantly produced porcine, bovine or other suitable donor/extraction insulin and mixtures of any of the above. The insulin may be neat (that is, in its substantially purified form), but may also include excipients as commercially formulated. Also included in the term “insulin” are insulin analogs where one or more of the amino acids of the naturally occurring or recombinantly produced insulin has been deleted or added.
It is to be understood that more than one active ingredient or agent may be incorporated into the aerosolized active agent formulation and that the use of the term “agent” or “ingredient” in no way excludes the use of two or more such agents. Indeed, some embodiments of the present invention contemplate filling a single dose container or a single disk with combination drugs that may be mixed in situ.
Examples of diseases, conditions or disorders that may be treated using dry powder filled with the filling systems of embodiments of the invention include, but are not limited to, asthma, COPD (chronic obstructive pulmonary disease), viral or bacterial infections, influenza, allergies, cystic fibrosis, and other respiratory ailments as well as diabetes and other insulin resistance disorders. The dry powder may be used to deliver locally-acting agents such as antimicrobials, protease inhibitors, and nucleic acids/oligionucleotides as well as systemic agents such as peptides like leuprolide and proteins such as insulin. For example, inhaler-based delivery of antimicrobial agents such as antitubercular compounds, proteins such as insulin for diabetes therapy or other insulin-resistance related disorders, peptides such as leuprolide acetate for treatment of prostate cancer and/or endometriosis and nucleic acids or ogligonucleotides for cystic fibrosis gene therapy may be performed. See e.g. Wolff et al., Generation of Aerosolized Drugs, J. Aerosol. Med. pp. 89-106 (1994). See also U.S. Patent Application Publication No. 20010053761, entitled Method for Administering ASPB28-Human Insulin and U.S. Patent Application Publication No. 20010007853, entitled Method for Administering Monomeric Insulin Analogs, the contents of which are hereby incorporated by reference as if recited in full herein.
Typical dose amounts of the unitized dry powder mixture dispersed by inhalers may vary depending on the patient size, the systemic target, and the particular drug(s). The dose amounts and type of drug held by a dose container (also known as a “dose container system”) may vary per dose container or may be the same on a platform such as a disk. In some embodiments, the dry powder dose amounts can be about 100 mg or less, typically less than 50 mg, and more typically between about 0.1 mg to about 30 mg.
In some embodiments, such as for pulmonary conditions (i.e., asthma or COPD), the dry powder can be provided as about 5 mg total weight (the dose amount may be blended to provide this weight). A conventional exemplary dry powder dose amount for an average adult is less than about 50 mg, typically between about 10-30 mg and for an average adolescent pediatric subject is typically from about 5-10 mg. A typical dose concentration may be between about 1-5%. Exemplary dry powder drugs include, but are not limited to, albuterol, fluticasone, beclamethasone, cromolyn, terbutaline, fenoterol, β-agonists (including long-acting β-agonists), salmeterol, formoterol, cortico-steroids and glucocorticoids.
In certain embodiments, the bolus or dose can be formulated with an increase in concentration (an increased percentage of active constituents) over conventional blends. Further, the dry powder formulations may be configured as a smaller administrable dose compared to the conventional 10-25 mg doses. For example, each administrable dry powder dose may be on the order of less than about 60-70% of that of conventional doses. In certain particular embodiments, using the dispersal systems provided by certain embodiments of the DPI configurations of the instant invention, the adult dose may be reduced to under about 15 mg, such as between about 10 μg-10 mg, and more typically between about 50 μg-10 mg. The active constituent(s) concentration may be between about 5-10%. In other embodiments, active constituent concentrations can be in the range of between about 10-20%, 20-25%, or even larger. In particular embodiments, such as for nasal inhalation, target dose amounts may be between about 12-100 μg.
In certain particular embodiments, the dry powder in the filling system for a particular dose container, drug compartment or blister may be formulated in high concentrations of an active pharmaceutical constituent(s) substantially without additives (such as excipients). As used herein, “substantially without additives” means that the dry powder is in a substantially pure active formulation with only minimal amounts of other non-biopharmacological active ingredients. The term “minimal amounts” means that the non-active ingredients may be present, but are present in greatly reduced amounts, relative to the active ingredient(s), such that they comprise less than about 10%, and preferably less than about 5%, of the dispensed dry powder formulation, and, in certain embodiments, the non-active ingredients are present in only trace amounts.
In some embodiments, the target unit dose amount of dry powder for a respective drug compartment or dose container is between about 5-15 mg, typically less than about 10 mg, such as about 5 mg of blended drug and lactose or other additive (e.g., 5 mg LAC), for treating pulmonary conditions such as asthma. Insulin may be provided in quantities of about 4 mg or less, typically about 3.6 mg of pure insulin. The dry powder may be inserted into a dose container/drug compartment in a “compressed” or partially compressed manner or may be provided as free flowing particulates.
The filling can be carried out to fill dose containers in any suitable number of doses, typically between about 30-120 doses, and more typically between about 30-60 doses.
Certain embodiments may be particularly suitable for dispensing medication to respiratory patients, diabetic patients, cystic fibrosis patients, or for treating pain. The inhalers may also be used to dispense narcotics, hormones and/or infertility treatments.
The dose filling systems may be particularly suitable for dispensing medicament for the treatment of respiratory disorders. Appropriate medicaments may be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (−)-4-amino-3,5-dichloro-α-[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl]benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person of skill in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimize the activity and/or stability of the medicament.
Some particular embodiments of the filling system can be used to dispense meted quantities of medicaments that are selected from the group consisting of: albuterol, salmeterol, fluticasone propionate and beclometasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol. Medicaments can also be delivered in combinations. Examples of particular formulations containing combinations of active ingredients include those that contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).
Turning now to the figures,
A retention and preload member (e.g., plate, cap and the like) 70 is positioned on the other side of the resilient member 60 and is mounted to a mounting member 80, such as a rigid block 80b that also supports the actuator 40. The mounting member 80 preferably has sufficient mass and/or weight to snugly hold the actuator 40 so as to inhibit translation. The mounting member 80 includes a clearance channel 80a for the tube 20. As shown, one end of the actuator 40 can be mounted to the member 80 and the other end of the actuator 40 can reside closely spaced to the flange 50, typically abutting the flange 50. In some embodiments, the lower end of the actuator 40 is affixed to the flange 50 (bonded, brazed, welded or otherwise attached) and the upper end of the actuator is affixed to the mounting member (e.g., bonded, brazed, welded or otherwise attached).
The retention member (e.g., plate, cap and the like) 70 can be attached to the mounting member 80 to preload the resilient member 60 with a force that compresses the resilient member 60.
As shown in
In some embodiments, the retention and pre-load member 70 may be integrated into the end cap or the body of the mounting member 80 such as via a ridge or other configuration so as to provide the pre-load at assembly and so as to not require a separate component (not shown).
The retention member 70 also includes a center through channel 70a and the tube 20 extends through this opening 70a. The mounting configuration of the actuator 40, tube 20, flange 50 and resilient member 60 allows the actuator 40 to vibrate the tube 20 axially and can compress the resilient member 60. The resilient member 60 can inhibit specific standing waves from forming along the tube. Due to the mass of the block and the mounting arrangement, the tube 20 can reciprocate, e.g., move axially back and forth a small distance, typically between about 0.5-100 microns, and more typically between about 2-20 microns, in response to the axially applied motion transmitted by the actuator 40.
As shown in
The tube 20 has a wall thickness 20th (
In some embodiments, the mounting member 80 (e.g., block 80b) can adjustably attach to a (typically stationary) coupler frame, bracket or housing 90 (
Referring to
It is also noted that although the actuator 40 is shown as mounted to a block 80, other rigid mounting configurations may be used while providing the tube through-channel, e.g., a plate, frame, disk, rod, cylinder and the like.
The vibration signal 20s can be selected to dispense dry powder at a defined flow rate (with acceptable variation, typically +/−5-10%) in response to the applied vibration signal 20s. The tube system can be configured so that the flow is controllable, e.g., there is no free-flow of powder out or through the tube 20 without the flow signal 20s.
In operation, a continual vibration signal or signals can be applied to the tube 20 and a “burst” of energy can be applied as the flow signal 20s for a short duration to carry out the replenishment of the dry powder bed 120 (
The signal 20s can be configured to generate less than about a 200 micron angular (axial) displacement of the tube 20, typically between about 2-20 microns as noted above. The frequency or frequencies of the flow signal 20s can be between about 80 Hz to about 5000 Hz, but other frequencies may be used. The signal can be a saw tooth, square, sinusoidal or other harmonic or non-harmonic signal profile. The vibration signal can be frequency modulated, e.g., a frequency modulated sinusoidal signal or amplitude modulated, e.g., an amplitude modulated sinusoidal signal. Powder-specific signals may be used. See, e.g., U.S. Pat. No. 6,985,798, the content of which is hereby incorporated by reference as if recited in full herein.
The feeding system 10 can flow powder 120 from a container/funnel 30 of a powder batch without inducing compaction, segregation of the blend, or undesirable changes to other physical properties of the batch. The system 10 can also provide improved precision of controlling start/stop flow control as well as regulation of the flow rate of moving powder to a pharmaceutical dosing head. The system 10 can flow pharmaceutical powders via axial vibration and gravity from a stationary hopper 30 to a filling head or dosing bowl 111 for dispensing (metering) powder into a dose pocket(s) 130c of a dose containment device.
It is contemplated that the feed system 10 can be used with any appropriate filling system or hopper. However, by way of example, the filling system 110 shown in
Where this type of filling system is used, the geometry of the channel 112, including one or more of the size of the orifice, size (volume and cross-sectional area) of the channel between the entry orifice and the exit port, shape and length of the channel and the size and shape of the exit port can be selected so that there is no “free flow” of powder out of the exit port when dispensing is not desired (e.g., when the vibratory flow signal is “off” or not transmitted to the flow channels). The channel geometry and the vibration flow signal can be selected to define a reliable flow rate with the “on” and “off” flow control corresponding to when the flow signal is applied or withheld without requiring any physical barrier or valving of the exit ports. The flow rates can be within a range of between about 5 mg/second to about 100 mg/second, typically between about 10 mg/second to about 30 mg/second. It may be desired to have the channel geometry and the signal provide a sub-second filling rate, e.g., a suitable flow rate for an “on” time for the vibratory flow signal of less than about 0.5 seconds to fill all 30 or 60 doses (or other numbers of dose containers). During filling, the dosing head 111 can reside closely spaced apart from (but not contacting) an underlying dose container member 130 with a plurality of spaced apart dose containers 130c. The spacing can be at distance “d”, typically between about 0.2-2 mm, and more typically between about 0.5-1 mm. The dry powder bed 111b with the dry powder 120 can be enclosed in a housing or open to atmosphere but is not required to be sealed in a pressurized chamber. That is, as the geometry of the channel and the vibratory flow signal directly dispense the dry powder into aligned dose containers 130c, neither pressure nor vacuum is required to dispense the dry powder and the dry powder bed can be environmentally protected from exposure but is not sealed in a pressure-tight manner.
Turning now to
The tube may extend through an actuator with a center channel aperture. The applying step can be carried out based on vibration transmitted by the actuator causing the tube to reciprocate axially and compress a resilient member (block 312). The method can include controlling a duration of the applying step to meter a defined amount of dry powder to a dry powder bed, wherein the flow is “on” in response to the axially applied vibration step and the flow is “off” when the axially applying step stops (block 314).
The method may include tuning the responsiveness of the tube to the vibration by selecting one or more of a wall thickness, length, and/or point of actuator attachment, to obtain free motion when the vibration is applied and no motion when the vibration is removed and the powder can flow through the tube at a rate of between about 100-500 mg/second during the axially applying step (block 315).
As shown in
The application programs 454 are illustrative of the programs that implement the various features of the data processing system 405 and preferably include at least one application which supports operations according to embodiments of the present invention. Finally, the data 456 represents the static and dynamic data used by the application programs 454, the operating system 452, the I/O device drivers 458, and other software programs that may reside in the memory 414.
While the present invention is illustrated, for example, with reference to the signal generator module 450 being an application program in
The I/O data port can be used to transfer information between the data processing system 405 and the feed/replenishment 10 or another computer system or a network (e.g., an intranet and/or the Internet) or to other devices controlled by the processor. These components may be conventional components such as those used in many conventional data processing systems which may be configured in accordance with the present invention to operate as described herein.
While the present invention is illustrated, for example, with reference to particular divisions of programs, functions and memories, the present invention should not be construed as limited to such logical divisions. Thus, the present invention should not be construed as limited to the configuration of
The flowcharts and block diagrams of certain of the figures herein illustrate the architecture, functionality, and operation of possible implementations of dry powder-specific dispensing and/or vibratory energy excitation means according to the present invention. In this regard, each block in the flow charts or block diagrams represents a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s). It should also be noted that in some alternative implementations, the functions noted in the blocks may occur out of the order noted in the figures. For example, two blocks shown in succession may in fact be executed substantially concurrently or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved.
In certain embodiments, the present invention can provide computer program products for operating a flowing dry powder tubular feeder system and a vibration energy source associated therewith to facilitate controlled flow. The computer program product can include a computer readable storage medium having computer readable program code embodied in the medium. The computer-readable program code can include: (a) computer readable program code that a plurality of different vibration energy signals associated with a “recipe” that correlates the formulation to the flow rate and desired replenishment amount; and (b) computer readable program code that directs the feed system to operate using the vibration energy signal for defined “on” and “off” times to dispense the desired amount (at the desired flow rate).
The following exemplary claims are presented in the specification to support one or more devices, features, and methods of embodiments of the present invention. While not particularly listed below, Applicant preserves the right to claim other features shown or described in the application.
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. Although a few exemplary embodiments of this invention have been described, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the claims. In the claims, means-plus-function clauses, where used, are intended to cover the structures described herein as performing the recited function and not only structural equivalents but also equivalent structures. Therefore, it is to be understood that the foregoing is illustrative of the present invention and is not to be construed as limited to the specific embodiments disclosed, and that modifications to the disclosed embodiments, as well as other embodiments, are intended to be included within the scope of the appended claims. The invention is defined by the following claims, with equivalents of the claims to be included therein.
This application claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 61/307,029 filed Feb. 23, 2010, the contents of which are hereby incorporated by reference as if recited herein.
Number | Name | Date | Kind |
---|---|---|---|
3216557 | Morris et al. | Nov 1965 | A |
3847191 | Aronson | Nov 1974 | A |
4116247 | Zanasi | Sep 1978 | A |
4630755 | Campbell | Dec 1986 | A |
4836417 | Uchiyama et al. | Jun 1989 | A |
4850259 | Morris | Jul 1989 | A |
5865012 | Hansson et al. | Feb 1999 | A |
5917266 | Murai | Jun 1999 | A |
5938075 | Murai et al. | Aug 1999 | A |
6050393 | Murai et al. | Apr 2000 | A |
6057515 | Murai et al. | May 2000 | A |
6226962 | Eason et al. | May 2001 | B1 |
6267155 | Parks et al. | Jul 2001 | B1 |
6357490 | Johnston et al. | Mar 2002 | B1 |
6886612 | Duffield | May 2005 | B2 |
6985798 | Crowder et al. | Jan 2006 | B2 |
7118010 | Crowder et al. | Oct 2006 | B2 |
20050040185 | Smith | Feb 2005 | A1 |
Entry |
---|
International Search Report and Written Opinion for corresponding PCT application No. PCT/US2011/025358, Date of mailing Sep. 29, 2011. |
Datasheet for Piezo Stack Actuator P-016.15H, Physik Instruments L.P., printed from website http://www.globalspec.com Feb. 17, 2011. |
Number | Date | Country | |
---|---|---|---|
20110204083 A1 | Aug 2011 | US |
Number | Date | Country | |
---|---|---|---|
61307029 | Feb 2010 | US |